Shire expanding rare-disease drug production; Cumberland gets new liver drug OK;

@FiercePharma: Will Watson get generic Lipitor market to itself? Article | Follow @FiercePharma

> Shire is adding patients for the Replagal and Vpriv treatments for rare disorders and increasing manufacturing capacity as larger drug companies seek to expand into the market for so-called orphan diseases. News

> Cumberland Pharmaceuticals said U.S. health regulators approved a new formulation of its drug for treating acetaminophen poisoning and it would replace the currently marketed product. Article

> Australia's Sigma Pharmaceuticals, which is selling its generic drugs unit to Aspen Pharmacare, cautioned that revenues will be negatively affected by changes in government pricing of generic medicines. Item

> German chemicals to real-estate company Evonik Industries AG said Friday it agreed on the purchase of pharmaceutical company Boehringer Ingelheim 's polymer portfolio, Resomer, in December. Item

> Icelandic generics manufacturer Actavis Group has formally opened a new €8 million expansion to its pharmaceutical manufacturing site in Hafnarfjordur. Actavis release | Story

 @FierceBiotech: Shulman: Best biotech stocks to own. Story | Follow @FierceBiotech

> Report: Sanofi readies $20B deal package for Genzyme. News 

> Allos lays off 13 percent of staff. Story 

> GSK malaria vax shows promising results. Item 

> Big Biotech joins Big Pharma in hunt for biosimilars. Report 

> BioCryst shares slide on peramivir trial revisions. Article

> Merck shares battered after it shutters vorapaxar trial. News

And Finally... If you are looking to lose weight in the coming year, you may need help from an unexpected place: the bacteria in your gut. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.